Drug
ERAS-601
ERAS-601 is a pharmaceutical drug with 5 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(60%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
5
100%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
3
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(1)
Terminated(1)
Detailed Status
Active, not recruiting3
Withdrawn1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 15 (100.0%)
Trials by Status
withdrawn120%
active_not_recruiting360%
completed120%
Recent Activity
3 active trials
Showing 5 of 5
active_not_recruitingphase_1
A Study of ERAS-601 in People With Chordoma
NCT06957327
active_not_recruitingphase_1
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04670679
active_not_recruitingphase_1
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04866134
completedphase_1
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
NCT04959981
withdrawnphase_1
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
NCT05279859
Clinical Trials (5)
Showing 5 of 5 trials
NCT06957327Phase 1
A Study of ERAS-601 in People With Chordoma
NCT04670679Phase 1
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04866134Phase 1
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04959981Phase 1
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
NCT05279859Phase 1
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5